Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Purchased by Fox Run Management L.L.C.

Fox Run Management L.L.C. boosted its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 149.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 23,290 shares of the biopharmaceutical company’s stock after buying an additional 13,966 shares during the period. Fox Run Management L.L.C.’s holdings in Celldex Therapeutics were worth $589,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in CLDX. EverSource Wealth Advisors LLC grew its holdings in shares of Celldex Therapeutics by 215.7% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 878 shares during the period. Swiss National Bank boosted its holdings in Celldex Therapeutics by 1.2% in the 4th quarter. Swiss National Bank now owns 117,300 shares of the biopharmaceutical company’s stock valued at $2,964,000 after purchasing an additional 1,400 shares during the last quarter. KBC Group NV grew its stake in shares of Celldex Therapeutics by 79.1% in the 4th quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company’s stock valued at $94,000 after buying an additional 1,647 shares during the period. Teachers Retirement System of The State of Kentucky increased its holdings in shares of Celldex Therapeutics by 5.1% during the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 42,628 shares of the biopharmaceutical company’s stock worth $1,449,000 after buying an additional 2,070 shares during the last quarter. Finally, AlphaQuest LLC raised its position in shares of Celldex Therapeutics by 171.0% during the 4th quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 2,705 shares during the period.

Celldex Therapeutics Stock Up 5.8 %

NASDAQ:CLDX opened at $20.78 on Tuesday. Celldex Therapeutics, Inc. has a 52 week low of $18.61 and a 52 week high of $47.00. The company has a fifty day simple moving average of $22.15 and a two-hundred day simple moving average of $26.86. The company has a market cap of $1.38 billion, a price-to-earnings ratio of -8.09 and a beta of 1.76.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.02. The company had revenue of $1.18 million for the quarter, compared to the consensus estimate of $1.25 million. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. On average, analysts expect that Celldex Therapeutics, Inc. will post -2.48 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on CLDX shares. UBS Group started coverage on Celldex Therapeutics in a research report on Thursday, February 13th. They issued a “buy” rating and a $44.00 price objective for the company. The Goldman Sachs Group reduced their price objective on shares of Celldex Therapeutics from $42.00 to $36.00 and set a “neutral” rating on the stock in a report on Monday, March 3rd. Morgan Stanley started coverage on shares of Celldex Therapeutics in a research report on Thursday, March 20th. They issued an “overweight” rating and a $46.00 target price on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $67.00 price target on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. Finally, HC Wainwright restated a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a report on Friday, February 28th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Celldex Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $54.33.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.